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Introduction
 
There is familial clustering in the incidence of diabetes-related
chronic complications [1], which suggests the existence of genetic
susceptibility to these complications. Many studies have
indicated that overactivity of the polyol pathway contributes
to the development of diabetic microvascular complications
by demonstrating the preventive effects of polyol pathway
inhibition on these complications [2]. Aldose reductase (AR)
is the rate-limiting enzyme of the polyol pathway, and thus
polymorphisms in the 
 
AR
 
 gene may be one of the factors that
determine genetic susceptibility to diabetic microvascular com-
plications [3,4]. Recently, a new polymorphism, C-106T, at
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Abstract
 
Aims
 
The aldose reductase (AR) gene, a rate-limiting enzyme of the polyol
pathway, has been investigated as a candidate gene in determining susceptibility
to diabetic microangiopathy. However, the association of the 
 
AR
 
 gene with
diabetic macroangiopathy has not been investigated. Therefore, the present study
was conducted to determine whether genetic variations of 
 
AR
 
 may determine
susceptibility to diabetic macroangiopathy.
 
Methods
 
There were 378 Type 2 diabetic patients enrolled in this study. A single
nucleotide polymorphism in the promoter region (C-106T) was genotyped and
the AR protein content of erythrocytes measured by ELISA.
 
Results
 
There were no significant differences in genotypic or allelic distribution
in patients with or without ischaemic heart diseases, but there was a significant
increase in the frequency of the CT + TT genotype and T allele in patients with
stroke (
 
P
 
 = 0.019 and 
 
P
 
 = 0.012). The erythrocyte AR protein content was
increased in patients with the CT and TT genotype compared with those with
the CC genotype. After adjustment for age, duration of diabetes, body mass
index, systolic blood pressure, HbA
 
1c
 
, and serum creatinine, triglycerides, and
total cholesterol in multivariate logistic-regression models, the association
between this 
 
AR
 
 genotype and stroke remained significant.
 
Conclusions
 
Our results suggest that the CT or TT genotype of the 
 
AR
 
 gene might
be a genetic marker of susceptibility to stroke in Type 2 diabetic patients. This
observation might contribute to the development of strategies for the prevention
of stroke in Type 2 diabetic patients.
Diabet. Med. 23, 894–899 (2006)
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position 
 
−
 
106 in the promoter region of AR, was identified
and an association with diabetic microangiopathy in Caucasian
and Asian subjects with Type 1 and Type 2 diabetes mellitus
has been reported [5–12].
Other reports have indicated a role of polyol pathway hyper-
activity in the development of diabetic macroangiopathy
 
in vivo
 
 [13,14] and 
 
in vitro
 
 [3,15,16]. Thus, the 
 
AR
 
 gene could
also be a predisposing factor to diabetic macroangiopathy.
However, the association of the 
 
AR
 
 gene with macroangiopathy
in diabetic subjects has never been reported.
To clarify these issues, the present study investigated whether
the C-106T polymorphism of the 
 
AR
 
 gene determines suscep-
tibility to diabetic macroangiopathy, such as ischaemic heart
disease and cerebrovascular disease, in Japanese Type 2 diabetic
patients and non-diabetic subjects.
 
Patients and methods
 
We screened 417 consecutive patients attending Nagoya
University Hospital. Patients with Type 1 diabetes (14), malignant
diseases (13) and other types of diabetes (steroid or pancreate-
ctomy induced; 10) were excluded. During screening, two patients
declined to participate. A total of 378 Type 2 diabetic outpatients
(28–88 years of age, 210 men and 168 women) were enrolled.
A total of 334 non-diabetic subjects (17–89 years of age, 206
men and 128 women) who underwent a medical check-up in
our hospital from April 2001 to December 2003 served as the
control group. They had fasting blood glucose levels < 6.1 mmol/l
and had no family history of diabetes. Five had an abnormal
electrocardiogram and 20 a history of atherosclerotic diseases.
Assessment and definition of diabetic macroangiopathy was
based on the following criteria. Cardiovascular disease was
defined by a history of ischaemic cardiovascular diseases (e.g.
previous myocardial infarction, angina, coronary-artery bypass
grafting). Stroke (ischaemic cerebrovascular disease) was diagnosed
by means of neurological signs and symptoms, together with com-
puted tomography or magnetic resonance imaging. According
to the Acute Stroke Treatment (TOAST) classification [17],
only large-vessel diseases and carotid stroke were enrolled, and
cardioembolic and lacunar stroke were excluded. Data regard-
ing the presence of peripheral vascular disease (PVD) were also
collected but the prevalence was too low to conduct statistical
analyses, and is not included in this paper. The study protocol
and informed consent procedure were approved by the Ethics
Committee of Nagoya University Hospital and was performed
in accordance with the Helsinki Declaration of 1975, as revised
in 1983.
 
Genotyping
 
DNA samples were prepared from whole blood using a QIAamp
DNA Blood Mini Kit (Qiagen, Chatsworth, CA, USA). The C-
106T polymorphism of the 
 
AR
 
 gene was determined by the
polymerase chain reaction restriction fragment length polymor-
phism method using the primers and conditions described by
Kao 
 
et al
 
. [5]. The presence of the C allele was indicated by a
206-bp fragment and T allele was indicated by 147- and 59-bp
fragments after overnight digestion with 
 
Bfa-I
 
 at 37
 
°
 
C. Before
enzymatic digestion with 
 
Bfa-I
 
, the product was purified with
QIAquick PCR Purification Kit (Qiagen). The AR protein
content in erythrocytes was measured by ELISA using anti-
human AR monoclonal antibody (Mitsubishi Gas Chemical,
Tokyo, Japan).
 
Statistical analysis
 
Statistical analyses were performed using SPSS for Windows
version 12.0 (SPSS, Chicago, IL, USA). Data are presented as
means 
 
±
 
 
 
SD
 
, unless otherwise indicated. Statistical significance
of the differences between the groups was determined by chi-square
(
 
χ
 
2
 
) tests, unpaired Student’s 
 
t
 
-tests or 
 
ANOVA
 
 where appropriate.
The Hardy–Weinberg test was performed using a standard
observed-expected 
 
χ
 
2
 
 test. Multiple logistic-regression analyses
were used to assess the association of the CT + TT genotype
with diabetic complications. Odds ratios (ORs) and their con-
fidence intervals (CIs) were used to estimate relative risk. A
two-sided 
 
P
 
-value less than 0.05 was considered statistically
significant.
 
Results
 
The clinical characteristics of diabetic patients and non-diabetic
subjects are presented in Table 1. The mean age, body mass
index (BMI), fasting blood glucose levels, systolic blood pressure
(SBP), diastolic blood pressure (DBP), and serum levels of
triglycerides and creatinine of diabetic patients were higher
than those of non-diabetic subjects. The high-density lipoprotein
(HDL) cholesterol of diabetic patients was lower than that of
non-diabetic subjects.
The genotype distributions of the C-106T polymorphism of
 
AR
 
 gene were 259 (68.5%) for CC, 105 (27.8%) for CT, and
14 (3.7%) for TT in the diabetic group, and 213 (63.8%) for
CC, 113 (33.8%) for CT, and 8 (2.4%) for TT in the non-
diabetic group. The frequencies of the C allele were 82.6% in
the diabetic group and 80.7% in the non-diabetic group. The
distribution of genotypes was in Hardy–Weinberg equilibrium.
There were no significant differences between the two groups
(genotype 
 
χ
 
2
 
 = 3.708 with 2 d.f., 
 
P
 
 = 0.157; allele 
 
χ
 
2
 
 = 0.698
with 1 df, 
 
P
 
 = 0.404).
Because the number of diabetic patients with the TT geno-
type was only 3.7%, subjects with the CT and TT genotypes
were combined for further analyses. The genotypes were not
associated with gender, duration of diabetes, age, diabetes
treatment, BMI, HbA
 
1c
 
 and fasting blood glucose levels, SBP,
DBP, serum levels of total cholesterol, triglycerides, HDL
cholesterol, low-density lipoprotein (LDL) cholesterol and
creatinine.
Table 2 shows the distribution of the C-106T polymorphism
in diabetic patients with or without ischaemic heart disease or
stroke. Stroke was more frequent in patients with the CT and
TT genotypes and T allele than those with the CC genotype
and C allele. However, there were no significant differences in
the prevalence of ischaemic heart disease between genotypes or
alleles. 
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We then compared the AR protein content in erythrocytes
among the genotypes. The AR content was significantly increased
in a genotype-dependent manner (CC, 11.2 
 
±
 
 2.5 ng/mg Hb; CT,
12.2 
 
±
 
  2.8  ng/mg Hb; TT, 13.9 
 
±
 
 2.9 ng/mg  Hb, 
 
P
 
 = 0.002
and 0.001 vs. CC; Fig. 1). However, there was no relationship
between AR content and presence of macroangiopathy.
Age (
 
P
 
 = 0.003), SBP (
 
P
 
 < 0.001), serum creatinine levels (
 
P
 
 =
0.008) and serum levels of triglycerides (
 
P
 
 = 0.048) were higher
in patients with a history of stroke.
Table 3 shows the results of multivariate logistic-regression
analyses with two models. After adjustment for age, SBP and
serum levels of creatinine and triglycerides in model 1, individuals
with the CT and TT genotypes were significantly more likely
to have had a stroke than individuals with the CC genotype
(OR 2.40, 95% CI 1.15–5.01, 
 
P
 
 = 0.019). Furthermore, in
model 2, after additional adjustment for HbA
 
1c
 
, BMI, serum
total-cholesterol levels and duration of diabetes, this relation-
ship remained (OR 2.79, 95% CI 1.27–6.13, 
 
P
 
 = 0.010).
 
Discussion
 
We have investigated the C-106T polymorphism in the promoter
region of the 
 
AR
 
 gene as a candidate gene for susceptibility
to diabetic macroangiopathy, and found that the CT or TT
genotype is associated with increased risk of stroke in Type 2
diabetic patients.
Diabetes mellitus is one of the major risk factors of coronary
heart disease and cerebrovascular disease. The high prevalence
of these macrovascular diseases in diabetic patients can be
explained by hyperglycaemia per se, as well as by the increased
frequency of conventional risk factors such as hypertension,
dyslipidaemia, and obesity.
Variable
Type 2 diabetic 
patients
Non-diabetic 
subjects P-value
n (male/female) 378 (210/168) 334 (206/128)  0.098
Duration of diabetes (years) 14.0 ± 9.5
Age (years) 62.5 ± 11.9 48.8 ± 12.8 < 0.001
Diabetes treatment (D/O/I/I+O)* 58/203/72/43
Body mass index (kg/m2) 23.4 ± 4.1 22.6 ± 3.1  0.002
HbA1c (%) 7.4 ± 1.4
Fasting blood glucose (mmol/l) 8.3 ± 2.7 4.9 ± 0.4 < 0.001
Systolic blood pressure (mmHg)  131 ± 16.8  122 ± 15.7 < 0.001
Diastolic blood pressure (mmHg)  74 ± 10.3  78 ± 11.3 < 0.001
Total cholesterol (mmol/l) 5.3 ± 0.94 5.2 ± 0.92  0.521
Triglycerides (mmol/l) 1.52 ± 0.90  1 ± 0.74 < 0.001
High-density lipoprotein cholesterol (mmol/l) 1.35 ± 0.40 1.46 ± 0.37  0.001
Low-density lipoprotein cholesterol (mmol/l) 3.2 ± 0.81 3.2 ± 0.85  0.809
Serum creatinine (mol/l)  82 ± 73.5  70 ± 14.1  0.004
Data are n or mean ± SD.
*D, diet only; O, oral glucose-lowering agents; I, insulin; I+O, insulin and oral glucose-lowering agents.
Table 1 Clinical characteristics of the study 
population
Table 2 Relationship between the AR genotype, allele and diabetic 
macroangiopathy in Japanese Type 2 diabetic patients
Ischaemic heart disease Stroke
–+ –+
Genotype
CC 84.0 (204) 16.0 (39) 92.2 (225) 7.8 (19)
CT + TT 85.0 (96) 15.0 (17) 84.1 (95) 15.9 (19)
P = 0.808 P = 0.019
Allele
C 84.3 (493) 15.7 (92) 91.0 (534) 9.0 (53)
T 84.3 (107) 15.7 (20) 83.5 (106) 16.5 (21)
P = 0.995 P = 0.012
Data are % (n).
P, two-sided χ2 test.
Figure 1 Erythrocyte AR contents of diabetic patients classified according 
to genotype of the C-106T polymorphism. Data are mean ± SD. 
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Accelerated proliferation of vascular smooth muscle cells
(SMCs) is one of the characteristic features of atherosclerosis
[18], and it has been proposed that hyperglycaemia contributes
to the hyperproliferation of SMCs [15,19]. Moreover, there
are some reports that the inhibition of the polyol pathway by
AR inhibitors prevents the enhanced proliferation of SMCs
cultured in high-glucose conditions [15,16,20] and also pre-
vents hyperglycaemia-induced NF-
 
κ
 
B activation [21] which is
involved in inflammatory signal transduction. We have pre-
viously shown that hyperactivity of the polyol pathway caused
intimal thickening of coronary arteries in the galactose-fed
dog, an animal model of polyol pathway hyperactivity, and
that this abnormality was ameliorated by treatment with an
aldose reductase inhibitor [13]. Taken together, these results
indicate that polyol pathway hyperactivity may be involved in
the hyperplasia of SMCs, and may play a substantial role in the
development of diabetic macroangiopathy. However, previous
studies have demonstrated that polyol pathway hyperactivity
contributes to the development of diabetic microangiopathy,
including neuropathy, nephropathy and retinopathy [2].
Hodgkinson 
 
et al
 
. [22] reported that there is a significant
correlation between increased AR expression, antioxidant gene
mRNA levels in peripheral mononuclear cells cultured in high
glucose and the CA repeat polymorphism of the 
 
AR
 
 gene in
patients with nephropathy. Furthermore, the CT or TT genotypes
and the T allele of this polymorphism have been identified as
genetic markers of susceptibility to diabetic microangiopathy
in several reports [5–12]. Therefore, genetic susceptibility to the
development of not only microvascular but also macrovascular
diseases in diabetes may be explained by the C-106T polymor-
phism of 
 
AR
 
 gene. However, a functional reporter gene assay
reported by Yang 
 
et al
 
. [23] showed that the promoter activity
of a construct containing the C allele is higher than of a construct
with the T allele in transfected HepG2 cells in high-glucose
conditions. Further studies will be required to clarify these
inconsistent results.
We showed that the CT and TT genotypes and the T allele
of the C-106T polymorphism in the 
 
AR
 
 promoter region are
thought to be a risk factor for stroke. Some independent effects
of genetic variants (e.g. prothrombin gene, factor V gene, meth-
ylenetetrahydrofolate reductase gene, apolipoprotein gene)
on the risk of cerebral ischaemia have been reported previously
[24]. Compared with these gene variants, the adjusted OR we
observed in this study suggests that the 
 
AR
 
 gene exerts a stronger
effect on the risk of stroke.
Makiishi 
 
et al
 
. reported, for the first time, the relationship
between the C-106T polymorphism of the 
 
AR
 
 gene and eryth-
rocyte AR content in Type 2 diabetic subjects [9]. The results
obtained in this study that AR contents were increased in
a genotype-dependent fashion (CC  <  CT  <  TT), are not
completely consistent with their observation, but do support
the hypothesis that polymorphisms of the 
 
AR
 
 gene influence
erythrocyte AR content and the development of diabetic com-
plications. Unfortunately, however, a significant relationship
between the AR content in erythrocytes and the prevalence of
stroke was not observed in our study.
Our findings should be cautiously interpreted because there
are some limitations to the present study. Our analysis of the
 
AR
 
 gene was limited to a single marker from the 5
 
′
 
 region of the
gene. Thus, it cannot be excluded that this 
 
AR
 
 polymorphism
is in linkage disequilibrium with an unidentified polymorphism
strongly related to stroke risk. This could explain the lack
of correlation between AR content in erythrocytes and the
prevalence of stroke. Hyperglycaemia, hyperosmolality, and
oxidative stress all regulate erthrocyte AR content [25–28],
and also contribute to the development of diabetic complica-
tions including macroangiopathy. Therefore, the strength of
the influence of these factors on erythrocyte AR content may
explain our unexpected results
There are several well-known conventional risk factors for
macrovascular diseases (for example, dyslipidaemia, hyper-
tension, hyperglycaemia, and increasing age) but little is known
about inherited factors that could predispose to diabetic
macroangiopathy. Among the conventional risk factors, in the
present study, age and systolic blood pressure were higher in
the subjects with stroke than those without stroke, although
the significance was weak after adjustment for various risk
factors. In contrast, the CT + TT genotype and the T allele of
the 
 
AR
 
 gene were associated with an increased risk of stroke,
and the significance of these genotypes remained high even after
adjustment for other risk factors. In addition, the erythrocyte
AR content was higher in the subjects with these genotypes.
Table 3 Odds ratios for associations between risk factors and the prevalence of stroke with the use of multivariate logistic-regression models
Variable
Odds ratio (95% CI) 
Model 1 P-value
Odds ratio (95% CI) 
Model 2 P-value
Age (years) 1.06 (1.02–1.10) 0.002 1.06 (1.01–1.11) 0.009
Systolic blood pressure (mmHg) 1.03 (1.01–1.06) 0.011 1.03 (1.00–1.05) 0.053
Serum creatinine (µmol/l) 1.40 (1.03–1.90) 0.029 1.39 (1.01–1.90) 0.043
Triglycerides (mmol/l) 1.63 (1.13–2.36) 0.009 1.62 (1.07–2.45) 0.024
AR genotype 2.40 (1.15–5.01) 0.019 2.79 (1.27–6.13) 0.010
HbA1c (%) 0.98 (0.70–1.37) 0.897
Body mass index (kg/m2) 1.01 (0.91–1.13) 0.802
Total cholesterol (mmol/l) 0.98 (0.63–1.53) 0.934
Duration of diabetes (years) 1.01 (0.97–1.06) 0.530 
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Therefore, it may be speculated that polymorphisms of the AR
gene, concomitant with an increase in erythrocyte AR content,
would increase vulnerability of brain arteries resulting in stroke.
However, prospective intervention studies with aldose reductase
inhibitors would be required to confirm the influence of the
AR gene polymorphism and AR content on the development
of stroke.
In contrast, it is noteworthy that the influence of this poly-
morphism on the development of ischaemic heart disease is
less than that on stroke. There are important differences in
risk factors for stroke and ischaemic heart disease. For stroke,
hypertension is the most adverse risk factor, whereas for
ischaemic heart diseases LDL cholesterol is the strongest.
This suggests that there are differences in the pathogenesis
of ischaemic heart disease and stroke, which might explain our
lack of association of the AR gene with ischaemic heart disease.
It can be speculated that brain vessels are more sensitive to polyol
pathway-induced hyperosmolar stress than coronary vessels.
Precise investigation will be required to clarify this issue.
It is important to replicate our results in other populations.
No previous study has investigated the relationship between
diabetic macroangiopathy and AR polymorphisms in other
populations. Although various studies have reported the
relationship between diabetic microangiopathy and AR poly-
morphisms [5–12], consistent results have not been obtained,
which may be as a result of differences between racial groups.
Further study would be required to clarify this issue.
In conclusion, we have found that the C-106T polymorphism
in the promoter region of the AR gene is associated with an
increased risk of stroke in Type 2 diabetic patients. This observa-
tion might contribute to the development of further strategies
for the prevention of stroke in Type 2 diabetic patients.
Competing interests
None declared.
Acknowledgements
We thank Dr Hiroshi Yatsuya for support in statistical analyses,
and Kimiko Sato and Yuko Maehata for technical support.
References
1 Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC.
Familial predisposition to renal disease in two generations of
Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus.
Diabetologia 1990; 33: 438–443.
2 Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential
target for the prevention of diabetic complications. Pharmacol Rev
1998; 50: 21–33.
3 Chung SS, Chung SK. Genetic analysis of aldose reductase in diabetic
complications. Current Med Chem 2003; 10: 1375–1387.
4 Demaine AG. Polymorphisms of the aldose reductase gene and
susceptibility to diabetic microvascular complications. Current Med
Chem 2003; 10: 1389–1398.
5 Kao YL, Donaghue K, Chan A, Knight J, Silink M. A novel polymor-
phism in the aldose reductase gene promoter region is strongly
associated with diabetic retinopathy in adolescents with type 1
diabetes. Diabetes 1999; 48: 1338–1340.
6 Moczulski DK, Scott L, Antonellis A, Rogus JJ, Rich CC, Warram JH
et al. Aldose reductase gene polymorphisms and susceptibility to
diabetic nephropathy in Type 1 diabetes mellitus. Diabet Med 2000;
17: 111–118.
7 Neamat-Allah M, Feeney SA, Savage DA, Maxwell AP, Hanson RL,
Knowler WC et al. Analysis of the association between diabetic
nephropathy and polymorphisms in the aldose reductase gene in
Type 1 and Type 2 diabetes mellitus. Diabet Med 2001; 18: 906–
914.
8 Wang Y, Ng MC, Lee SC, So WY, Tong PC, Cockram CS et al.
Phenotypic heterogeneity and associations of two aldose reductase
gene polymorphisms with nephropathy and retinopathy in type 2
diabetes. Diabetes Care 2003; 26: 2410–2415.
9 Makiishi T, Araki S, Koya D, Maeda S, Kashiwagi A, Haneda M.
C-106T polymorphism of AKR1B1 is associated with diabetic
nephropathy and erythrocyte aldose reductase content in Japanese
subjects with type 2 diabetes mellitus. Am J Kidney Dis 2003; 42:
943–951.
10 Sivenius K, Niskanen L, Voutilainen-Kaunisto R, Laakso M,
Uusitupa M. Aldose reductase gene polymorphisms and susceptibility
to microvascular complications in Type 2 diabetes. Diabet Med 2004;
21: 1325–1333.
11 Sivenius K, Pihlajamäki J, Partanen J, Niskanen L, Laakso M,
Uusitupa M. Aldose reductase gene polymorphisms and peripheral
nerve function in patients with type 2 diabetes. Diabetes Care 2004;
27: 2021–2026.
12 Gosek K, Moczulski D, Zukowska-Szczechowska E, Grzeszczak W.
C-106T polymorphism in promoter of aldose reductase gene is a risk
factor for diabetic nephropathy in type 2 diabetes patients with poor
glycaemic control. Nephron Exp Nephrol 2005; 99: E63–E67.
13 Kasuya Y, Ito M, Nakamura J, Hamada Y, Nakayama M, Chaya S
et al. An aldose redutase inhibitor prevents the intimal thickening
in coronary arteries of galactose-fed beagle dogs. Diabetologia 1999;
42: 1404–1409.
14 Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB,
Srivastava SK. Aldose reductase mediates mitogenic signaling in
vascular smooth muscle cells. J Biol Chem 2002; 277: 32063–32070.
15 Nakamura J, Kasuya Y, Hamada Y, Nakashima E, Naruse K,
Yasuda Y et al. Glucose-induced hyperproliferation of cultured rat
aortic smooth muscle cells through polyol pathway hyperactivity.
Diabetologia 2001; 44: 480–487.
16 Li W, Hamada Y, Nakashima E, Naruse K, Kamiya H, Akiyama N et al.
Suppression of 3-deoxyglucosone and heparin-binding epidermal
growth factor-like growth factor mRNA expression by an aldose
reductase inhibitor in rat vascular smooth muscle cells. Biochem
Biophys Res Commun 2004; 314: 370–376.
17 Adams HP, Woolson RF, Biller J, Clarke W. Studies of Org 10172 in
patients with acute ischemic stroke. TOAST Study Group. Haemostasis
1992; 22: 99–103.
18 Ross R. The pathogenesis of atherosclerosis: a perspective for the
1990s. Nature 1993; 362: 801–809.
19 Yasunari K, Kohno M, Kano H, Yokokawa K, Horio T, Yoshikawa J.
Aldose reductase inhibitor prevents hyperproliferation and hyper-
trophy of cultured rat vascular smooth muscle cells induced by high
glucose. Arterioscler Thromb Vasc Biol 1995; 15: 2207–2212.
20 Kasuya Y, Nakamura J, Hamada Y, Nakayama M, Sasaki H,
Komori T et al. An aldose reductase inhibitor prevents the glucose-
induced increase in PDGF-β receptor in cultured rat aortic smooth
muscle cells. Biochem Biophys Res Commun 1999; 261: 853–858.
21 Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK.
Activation of nuclear factor-κB by hyperglycemia in vascular smooth
muscle cells is regulated by aldose reductase. Diabetes 2004; 53:
2910–2920.Original article 899
© 2006 The Authors. 
Journal compilation © 2006 Diabetes UK. Diabetic Medicine, 23, 894–899
22 Hodgkinson AD, Bartlett T, Oates PJ, Millward BA, Demaine AG.
The response of antioxidant genes to hyperglycemia is abnormal
in patients with type 1 diabetes and diabetic nephropathy. Diabetes
2003; 52: 846–851.
23 Yang B, Millward A, Demaine A. Functional differences between the
susceptibility Z-2/C-106 and protective Z+2/T-106 promoter region
polymorphisms of the aldose reductase gene may account for the
association with diabetic microvascular complications. Biochim
Biophys Acta 2003; 1639: 1–7.
24 Pezzini A, Grassi M, Del Zotto E, Archetti S, Spezi R, Vergani V
et al. Cumulative effect of predisposing genotypes and their interac-
tion with modifiable factors on the risk of ischemic stroke in young
adults. Stroke 2005; 36: 533–539.
25 Henry DN, Del Monte M. Greene DA. Killen PD. Altered aldose
reductase gene regulation in cultured human retinal pigment epi-
thelial cells. J Clin Invest 1993; 92: 617–623.
26 Ko BC, Ruepp B, Bohren KM, Gabbay KH, Chung SS. Identification
and characterization of multiple osmotic response sequences in
the human aldose reductase gene. J Biol Chem 1997; 272: 16431–
16437.
27 Ruepp B, Bohren KM, Gabbay KH. Characterization of the osmotic
response element of the human aldose reductase gene promoter. Proc
Natl Acad Sci USA 1996; 93: 8624–8629.
28 Spycher SE, Tabataba-Vakili S, O’Donnell VB, Palomba L, Azzi A.
Aldose reductase induction: a novel response to oxidative stress of
smooth muscle cells. FASEB J 1997; 11: 181–188.